Immunotherapeutic options on the horizon in breast cancer treatment.

  title={Immunotherapeutic options on the horizon in breast cancer treatment.},
  author={Johan M. van Rooijen and Thijs S Stutvoet and Carolina P. Schr{\"o}der and Elisabeth G. E. de Vries},
  journal={Pharmacology & therapeutics},
It is increasingly acknowledged that breast cancer can be an immunogenic disease. Immunogenicity appears to differ between subtypes. For instance, in triple negative breast cancer (TNBC) and HER2-positive breast cancer tumor infiltrating lymphocytes (TILs) are prognostic and predictive for response to chemotherapy containing anthracyclines, but in other subtypes they are not. Preclinical evidence suggests important immune based mechanisms of conventional chemotherapeutics, in particular… CONTINUE READING
Highly Cited
This paper has 42 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS


Publications citing this paper.

Similar Papers

Loading similar papers…